bio-11006
Peptideexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00648245)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Myristoylated alanine-rich C-kinase substrate inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297701 ↗
Also known as
- bio-11006
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04183062 | Phase 2 | Oct 4, 2019 | Florida International University |
| NCT03472053 | Phase 2 | Feb 1, 2018 | Biomarck Pharmaceuticals, Cliantha Research Limited |
| NCT03202394 | Phase 2 | Jul 5, 2017 | Biomarck Pharmaceuticals |
| NCT00648245 | Phase 2 | Jun 1, 2008 | Biomarck Pharmaceuticals, National Heart, Lung, and Blood Institute (NHLBI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biomarck Pharmaceuticals | For profit | 3 | 3 | 1 | 2008 |
| Cliantha Research Limited | For profit | 1 | 0 | 1 | 2018 |
| Florida International University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1